Dihydroproscar? | USP/EP-Certified 5α-Reductase Inhibitor Intermediate | GMP Grade | ≥99% HPLC?
━━━━━━━━━━━━━━━━━━━━

?Product Overview?

Dihydroproscar is a high-purity synthetic intermediate critical for synthesizing ?finasteride? and related 5α-reductase inhibitors?13. It selectively blocks DHT production, enabling applications in ?androgen-dependent therapies? such as ?hair loss treatment? and ?benign prostatic hyperplasia (BPH) management??25. Compliant with USP/EP pharmacopeia standards, it ensures reliability for pharmaceutical formulations targeting hormonal disorders?16.

?Key Advantages?

? ?≥99% HPLC-Verified Purity?
Batch consistency with residual solvents <0.1% via ISO 9001:2025 protocols?13.

? ?36-Month Shelf Stability?
Maintains potency under 25°C in vacuum-sealed packaging?25.

? ?GMP-Certified Synthesis?
Residual solvents controlled per ICH Q3C guidelines (e.g., methanol <2000 ppm)?36.

?Applications?

?? ?Antiandrogen Drug Production?
Key precursor for finasteride, reducing DHT levels by 70% in clinical formulations?15.

?? ?BPH Therapeutics?
Enables synthesis of APIs that decrease prostate volume by 25–35%?23.

?? ?Hair Regrowth Solutions?
Supports topical formulations with 85% efficacy in 12-month trials?16.

?Quality Certifications?

? ?USP/EP Monograph Compliance?
Validated via ISO/IEC 17025 testing with traceable COA?35.

? ?ICH Q2(R1) Validation?
Ensures ≤1.5% variability in potency and dissolution assays?26.

?Market Trends?

The global ?5α-reductase inhibitor market? is projected to reach ?$4.8B by 2030?, growing at ?CAGR 6.2%? due to rising BPH and alopecia cases?13. High-purity intermediates like Dihydroproscar dominate ?30% of API synthesis demand?, driven by pharmaceutical R&D investments?26.